A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN 74809 in participants with primary sclerosing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC).

Roberts, Stuart (Primary Chief Investigator (PCI))
Adams, Leon Anton (Chief Investigator (CI))
George, Jacob (Chief Investigator (CI))
Strasser, Simone Irene (Chief Investigator (CI))
Thompson, Alexander J.V. (Chief Investigator (CI))
Lynch, Kate (Chief Investigator (CI))

Gastroenterology

Project: Research

Project Description

Protcol number PLN-74809-PSC-203

Status	Active
Effective start/end date	1/10/20 → 1/11/23

Keywords

Gastroenterology
Primary Sclerosing Cholangitis
Liver fibrosis
Clinical trial